Clinical Trial
Adjuvant Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
Learn more about this study at
clinicaltrials.gov
For more information contact us here:
Phone
800-600-3606Brief Summary
This is an open-label, single center, one cohort, non-randomized, phase II study. The aim is to evaluate the efficacy and safety of the combination of hypofractionated radiotherapy (HRT) and pembrolizumab on local tumor control in mucosal melanoma patients. Treatment effect will be compared with historical radiation therapy-alone control data.
Protocol Interventions
Drug: Pembrolizumab, Radiation: Hypofractionated radiation therapy
Learn About Clinical Trials
Clinical trials are research studies that help us find new ways to prevent, diagnose, and treat cancer. If you are interested in participating in a clinical trial, our team will help you find a study that is right for you. Call us to speak with a Siteman care coordinator.